Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA

被引：0
|
作者：
Decker, Thomas
Brucker, Cosima
Engel, Anne
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Lueftner, Diana
van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Roos, Christian
Woeckel, Achim
机构：
[1] Onkol Ravensburg, Ravensburg, Germany
[2] Paracelsus Med Univ, Univ Womens Hosp, Nurnberg, Germany
[3] Winicker Norimed GmbH, Nurnberg, Germany
[4] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany
[5] Onkozentrum Dresden Freiberg, Dresden, Germany
[6] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany
[7] Med Studiengesell Nord West GmbH, Westerstede, Rhauderfehn, Germany
[8] Practice Hematol & Oncol, Langen, Germany
[9] Niels Stensen Kliniken, Dept Hematol & Oncol, Georgsmarienhutte, Germany
[10] Med Univ Brandenburg, Immanuel Klin Markische Schweiz, Buckow, Germany
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
[12] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[13] Practice Hematol & Internal Oncol, Velbert, Germany
[14] Univ Klinikum Freiburg, Freiburg, Germany
[15] Univ Klinikum Rostock, Rostock, Germany
[16] Johannes Gutenberg Univ Mainz, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[17] InVO GbR, Koblenz, Germany
[18] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[19] Novartis Pharma GmbH, Nurnberg, Germany
[20] Univ Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13050
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Ribociclib (RIBO) plus letrozole (LET) in older patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial
    Ring, A.
    Borstnar, S.
    Ferreira, A.
    Azim, H. A.
    Cottu, P.
    Lu, J.
    Martin, M.
    Zamagni, C.
    Beck, J. T.
    Zhou, K.
    Wu, J.
    Menon, L.
    De laurentiis, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
    Cottu, P. H.
    Ring, A.
    Marchetti, P.
    Cardoso, F.
    Salvador, J.
    Neven, P.
    Papazisis, K.
    Campone, M.
    Bachelot, T.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S379 - S380
  • [43] A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1
    Rugo, Hope S.
    Andre, Fabrice
    Rubovszky, Gabor
    Kaufman, Bella
    Inoue, Kenichi
    Takahashi, Masato
    Shimizu, Satoru
    Ciruelos, Eva M.
    Campone, Mario
    Conte, Pier Franco
    Iwata, Hiroji
    Loibl, Sibylle
    Mayer, Ingrid A.
    Juric, Dejan
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Sellami, Dalila B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study
    Fasching, P. A.
    Decker, T.
    Guderian, G.
    Heim, J.
    Jackisch, C.
    Lueck, H-J.
    Lueftner, D.
    Marme, F.
    Reimer, T.
    Woeckel, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Sellami, Dalila
    El-Hashimy, Mona
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    Baselga, Jose
    CANCER RESEARCH, 2018, 78 (04)
  • [46] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
    Cristofanilli, Massimo
    Rugo, Hope S.
    Im, Seock-Ah
    Slamon, Dennis J.
    Harbeck, Nadia
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Iwata, Sherene Loi Hiroji
    O'Leary, Ben
    Bananis, Eustratios
    Liu, Yuan
    Huang, Xin
    Kim, Sindy
    Lechuga, Mariajose
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Real-world effectiveness of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Baseline data from the RIBANNA study.
    Woeckel, Achim
    Decker, Thomas
    Fasching, Peter A.
    Jackisch, Christian
    Luftner, Diana
    Marme, Frederik
    Reimer, Toralf
    Roos, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
    Salvador, J.
    Ciruelos, E. M.
    Prat, A.
    Jimenez-Rodriguez, B.
    de la Cruz, L.
    Martinez, N.
    Villanueva Vazquez, R.
    de Toro, R.
    Anton, A.
    Moreno, F.
    Alvarez, I.
    Gavila, J.
    Quiroga, V.
    Vicente, E.
    de la Haba, J.
    Gonzalez-Santiago, S.
    Diaz, N.
    Barnadas, A.
    Cantos Sanchez de Ibarguen, B.
    Delgado, J. I.
    Bellet, M.
    Gimeno, A.
    Sanz, S.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012
    Swallow, Elyse
    Zhang, Jie
    Thomason, Darren
    Tan, Ruo-Ding
    Kageleiry, Andrew
    Signorovitch, James
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1537 - 1545
  • [50] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345